Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy

Autor: Jain, Hasmukh ^*, Karulkar, Atharva ^*, Sharma, Neha ^*, Sengar, Manju, Jaiswal, Ankesh ^*, Shah, Shreshtha ^*, Khan, Aalia ^*, Firfiray, Afrin ^*, Asija, Sweety ^*, Suvasia, Prashant ^*, Suvasia, Priyanshi ^*, Pendhari, Juber ^*, Kalra, Devanshi ^*, Ravikumar, Smrithi ^*, Narula, Gaurav ^*, Banavali, Shripad ^*, Poojary, Minal ^*, Hiregoudar, Sumathi ^*, Nayak, Lingaraj ^*, Bagal, Bhausaheb ^*, Tembhare, Prashant R., Epari, Sridhar ^*, Khattry, Navin ^*, Patkar, Nikhil ^*, Gujral, Sumeet ^*, Shet, Tanuja ^*, Subramanian, Papagudi Ganesan ^*, Thorat, Jayashree ^*, Punatar, Sachin ^*, Gokarn, Anant ^*, Ghosh, Kinjalka ^*, Agarwal, Archi ^*, Desai, Preeti ^*, Ojha, Shashank ^*, Yadav, Subhash ^*, Bhosale, Shil Pushp ^*, Rajadhyaksha, Sunil ^*, Navkudkar, Anisha ^*, Laskar, Siddharth ^*, Mirgh, Sumeet Prakash ^*, Nisar, Albeena ^*, Pandit, Deepali ^*, Patil, Ruchira ^*, Purwar, Rahul ^*, Neelapu, Sattva S., Shah, Nirali N.

Publikováno v: In Blood 15 November 2022 140 Supplement 1:10332-10334

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.